Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

well-tolerated and may represent a benefit for patients in terms of convenience and ease of administration. Tanespimycin is clearly an active and manageable agent and is deserving of further clinical study."

"We continue to see meaningful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma across patient populations. In addition, we are observing intriguing evidence supporting the hypothesis that in the tanespimycin/bortezomib combination, tanespimycin may be exerting a neuroprotective effect based on the observation of reduced neuropathy, a side effect associated with bortezomib," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "The data from this ongoing trial are still being evaluated, and multiple patients remain on study. At this time, the overall response rate appears to be lower than previously reported. We are investigating whether there were patient characteristics that may have contributed to this lower response rate, including the possibility that patients added to the study since the data were last reported represented a more advanced and heavily pretreated population. We will complete the study and further evaluate the data in consultation with multiple myeloma experts to confirm the most expeditious course forward. Taken as a whole, the currently available data from this trial suggest that there may be utility in adjusting the TIME program to optimize the therapeutic potential of the tanespimycin and bortezomib combination. We have not, however, made any definitive decisions concerning a potential adjustment."

Tanespimycin Phase 1b Trial Results

The objective of the Phase 1b dose-escalating trial was to evaluate tanespimycin with bortezomib in patients with relapsed, refractory multiple myeloma, relative to safety, pharmacokinetic, pharmacodynamic and anti-myeloma effects. Dose escalations in the entire trial ranged from 100-340 mg/m2 for
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... India , September 3, 2015 ... Metallic compounds, Organosulfurs, Organic acids, Phenolics, and Others) and ... & beverage, Paints & coatings, and Others) - Global ... and segments the Biocides Market with an analysis and ... as value. Browse   88 tables ...
(Date:9/2/2015)... Balloon angioplasty is a minimally invasive ... report is on global angioplasty balloons studies the ... report comprises an elaborate executive summary, which includes ... various segments and sub-segments included in the study. ... data analysis of the global angioplasty balloons market ...
(Date:9/2/2015)... , Sept. 2, 2015 About ... artificial implants used to replace, augment, or repair ... a wide range of applications including cosmetic, spinal, ... are made of different materials such as polymers, ... the global implantable medical devices market to grow ...
Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Implantable Medical Devices Market 2015-2019 2
... Corporation (NYSE: GPX ), announced today that ... with and into its wholly-owned subsidiary, General ... Physics, which is the sole operating subsidiary of GP ... be renamed GP Strategies Corporation when the merger becomes ...
... 15, 2011  MedAssurant, Inc., a leading provider ... Healthcare Partners, IPA (HCPIPA), one of the ... the Northeast, has selected MedAssurant,s Prospective Advantage® ... proactively identify gaps in care and quality ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an ... Google Play , and Amazon and will be released on DVD early ... Darling is a Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from ...
(Date:9/3/2015)... ... 2015 , ... At Renew Man™, we have seen an increasing number of ... where the primary care physician dictates and the patient obeys. Instead, our clients are ... health issues and empowered to choose their own treatment options. , Recognizing that many ...
(Date:9/3/2015)... , ... September 03, 2015 , ... James Earl Jones ... workplace wellness. In this episode, James Earl Jones will introduce a segment that discusses ... unhealthy workplace and how workplace wellness can be fostered in any working environment. , ...
(Date:9/3/2015)... ... September 03, 2015 , ... Fashion designer Kim (29 years old, ... most recent episode of the hit ABC series “Extreme Weight Loss” Season 5 ... her industry. She provided herself with the motivation to transform when she designed a ...
(Date:9/2/2015)... ... September 03, 2015 , ... Sara ... Bloomberg School of Public Health and an internationally recognized scholar on obesity prevention ... 2015-16. Dr. Bleich, a Baltimore native and 1996 graduate of Garrison Forest School, ...
Breaking Medicine News(10 mins):Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 2Health News:New “Extreme Weight Loss” Video Blog from the CU Anschutz Health and Wellness Center: Kim Begins with the End in Mind and Designs a Fashionable Future 3Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2
... international team of scientists led by researchers at the University ... pluripotent stem cells (iPSCs) derived from patients with amyotrophic lateral ... levels of a specific protein may play a central role ... The work, published in the June 2011 online issue ...
... By Alan Mozes HealthDay Reporter , TUESDAY, June ... research suggests that repeated bouts of unemployment don,t affect everyone ... people who are consistently successful in finding new work after ... so-called "serial joblessness" than are those who lose a job ...
... strong evidence indicates that policies beyond the health sector ... U.S. government should adopt a structured approach to considering ... says a new report by the Institute of Medicine. ... and revise public health laws so that they adequately ...
... Reporter , MONDAY, June 20 (HealthDay News) -- Evaluating ... lower blood pressure requires multiple readings, new research suggests. ... condition known as "white coat" hypertension, so readings should ... study,s lead author, Dr. Benjamin Powers, assistant professor of ...
... laid, their natural resistance to pathogens begins to wear down, ... rearm those defenses. Kevin Keener, an associate professor of ... is designed to inhibit the growth of bacteria such as ... an egg with carbon dioxide and alter pH levels, which ...
... cancer who don,t live near a major academic medical center ... The University of Alabama at Birmingham Comprehensive Cancer Center ... bring leading-edge care to these communities, giving patients an opportunity ... access to leading cancer research. The UAB ...
Cached Medicine News:Health News:Stem cell model offers clues to cause of inherited ALS 2Health News:Unemployment May Hit Some Harder Than Others 2Health News:Unemployment May Hit Some Harder Than Others 3Health News:Unemployment May Hit Some Harder Than Others 4Health News:Government should consider public health implications of all major legislation 2Health News:Single Reading Can't Gauge Blood Pressure Control: Study 2Health News:Single Reading Can't Gauge Blood Pressure Control: Study 3Health News:Cooling system may build eggs' natural defenses against salmonella 2Health News:UAB Comprehensive Cancer Center launches Cancer Care Network 2
... is an economically priced 4-channel data ... research use in the fields of ... biology, zoology, biochemistry and biomedical engineering. ... signal conditioners and transducers. Two Pod ...
Near PT test card/Tumbling E, tumbling hands 5 1/2" X 8"....
Tumbling E/20' distance chart 22-1/2" X 11" 20/200 to 20/10....
... charts contain 5 pages of various contrast levels ... size is 9.5M. Contrast levels are 25%, 10%, ... be used at several different distances. These two ... offers a different set of symbols to ...
Medicine Products: